Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrate CRISPR/Cas9 for protein expression of HLA-B*38:68Q via precise gene editing.

Scientific reports - 30 May 2019

Yin Yuxin, Reed Elaine F, Zhang Qiuheng

Abstract excerpt

The determination of null- or low-expressed HLA alleles is clinically relevant in both hematopoietic stem cell transplantation and solid organ transplantation. We studied the expression level of a questionable (Q) HLA-B*38:68Q allele, which carries a 9-nucleotide (nt) deletion at codon 230-232 in exon 4 of HLA-B*38:01:01:01 using CRISPR/Cas9 gene editing technology. CRISPR/Cas9 gene editing of HLA-B*38:01:01:01...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B-Lymphocytes
Share to CRISPR-Cas Systems
Share to Feasibility Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Editing

Share to Herpesvirus 4, Human

Share to Histocompatibility Testing

Share to Homozygote

Share to Sequence Deletion

Source

Open in PubMed Open full text

Identifiers

PMID: 31147565
DOI: 10.1038/s41598-019-44336-7
PMCID: PMC6542842

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrate CRISPR/Cas9 for protein expression of HLA-B*38:68Q via precise gene editing.PMID 31147565Read ↗

Abrogation of HLA surface expression using CRISPR/Cas9 genome editing: a step toward universal T cell therapySemantic proximity Read ↗

HLA-Knockout: Enabling Allele-Specific Knockout of HLA Class I Genes for Immunogenic Engineering.Semantic proximity Read ↗

Antigen Presentation by Individually Transferred HLA Class I Genes in HLA-A, HLA-B, HLA-C Null Human Cell Line Generated Using the Multiplex CRISPR-Cas9 SystemSemantic proximity Read ↗

B2M gene knockout in HEK293T cells by non-viral delivery of CRISPR-Cas9 for the induction of universal cellSemantic proximity Read ↗

Innovative CRISPR/Cas9-Based Strategy for Allele-Specific HLA Peptidome Analysis Using a Pan-HLA Antibody.Semantic proximity Read ↗

Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune CompatibilitySemantic proximity Read ↗

Generation of hypoimmunogenic universal iPSCs through HLA-type gene knockoutSemantic proximity Read ↗

HLA-G neo-expression modifies genetic programs governing tumor cell linesSemantic proximity Read ↗

Expression profile of HLA-B*38:55Q allele.Semantic proximity Read ↗

Genome editing HLA alleles for a pilot immunocompatible hESC line in a Chinese hESC bank for cell therapies.Semantic proximity Read ↗

Allo-defensive, multiplex base-edited, anti-CD38 CAR T cells for ‘off-the-shelf’ ImmunotherapySemantic proximity Read ↗

[Using Next-Generation Sequencing Technology to Confirm the HLA Rare Alleles Detected by PCR-SSOP].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.